Yonghe Medical Group (SEHK:2279) Stock Rebounds As Profit Turnaround Gains Credibility

Yonghe Medical Group stock closed at HK$2.49 on Friday after a flat week and a strong 30 day rebound, yet the real story sits in the earnings line. The market is still pricing a low P/E of 8.8x for a healthcare provider that has moved from multi year losses to a trailing twelve month profit of CNY 121.3 million.

The headline from this half year release is clear. Profitability is no longer a theory. Basic earnings per share for H1 2026 came in at CNY 0.15 and the recent return to the black now frames every long term forecast and valuation debate around Yonghe Medical Group.

Love the turnaround in Yonghe Medical Group earnings but want more companies with similar profit traction and balance sheet strength on your radar? Check out our curated set of list of solid balance sheet and fundamentals stocks (426 results).

H1 2026 Earnings Summary

• Revenue (H1 2026 vs. H1 2025): CNY 980.638 million vs. CNY 861.55 million (higher period on period)
• Net income, excluding extra items (H1 2026 vs. H1 2025): CNY 75.521 million vs. CNY 27.913 million (higher period on period)
• Basic EPS (H1 2026 vs. H1 2025): CNY 0.15 vs. CNY 0.055798 (higher period on period)
• Trailing 12-month net income, excluding extra items (TTM to H1 2026 vs. TTM to H1 2025): CNY 121.319 million vs. a loss of CNY 59.858 million (moved from loss to profit over the year)

Prefer clear visuals instead of another wall of earnings tables and ratios? See Yonghe Medical Group's full valuation picture laid out in simple charts in the company report for Yonghe Medical Group.

Yonghe Medical Group earnings backing a cautious bull story

For investors leaning positive on Yonghe Medical Group, the latest half year numbers give the story more substance. Revenue for H1 2026 is higher than H1 2025 and net income excluding extra items has also risen. Basic EPS has improved, and the trailing twelve month line now shows a profit instead of a loss. This points to a business model that is starting to turn operational scale into cleaner earnings, which helps the idea of a focused hair health platform with multiple service lines.

Short term risks and bearish angles after the rebound

Cautious investors will focus on how fragile this profitability may still be. Yonghe Medical Group only recently moved from a trailing twelve month loss to profit, so there is limited history of sustained earnings. The stock has also pulled back slightly over the past week after a strong 30 day run, which suggests sentiment can cool quickly. In a consumer facing healthcare niche that relies on steady patient flows and brand trust, any setback in demand or cost control could quickly compress these still modest profit levels.

Compare Yonghe Medical Group's new profit profile with what institutional analysts are signaling. See the consensus price target analysis for Yonghe Medical Group to check how current targets line up with this turnaround story.

Stay Ahead With Simply Wall St

If Yonghe Medical Group's move from multi year losses to a trailing profit has your attention, register for free with Simply Wall St and add it to a Watchlist to track the share price against fair value and watch for your preferred entry point. Once you are invested, use the Portfolio Command Center to cut through noise and focus on the most important updates for your holdings. For a longer term view, tap into crowd insights and different investor angles through the Community. This way you can spot potential catalysts and risks early and stay a step ahead of the market.

Seeking Alternatives Beyond Yonghe Medical Group

Fresh ideas can move fast when momentum builds and early data is still under the radar for now. Scan these focused shortlists before the best entry points get caught. Consider reviewing the following areas:

• Identify cash-generative compounders early and review a curated 270 high quality undervalued stocks that many investors may only notice after the momentum is already established.
• Consider the infrastructure side of the AI buildout and track a hand-picked mix of 55 AI infrastructure stocks before valuations respond to any changes in sentiment.
• Review potential changes in power demand and scan through carefully filtered 39 power grid technology and infrastructure stocks while these stories remain less widely followed.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com